Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsMihaly Hajos, PharmD, PhD
Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Professor Adjunct
Biography
Mihaly Hajos is a Professor Adjunct at the Section of Comparative Medicine, leading the Laboratory of Translational Neuropharmacology. He received a Pharm.D. degree from Albert Szent-Gyorgyi Medical University, Szeged, Hungary, and a Ph.D. from University of Goteborg, Sweden. His research interest includes neurobiology and pharmacology of psychiatric and neurological disorders, application of systems electrophysiology in drug discovery, and translational aspects of neurophysiological measures from preclinical to clinical studies.
Last Updated on April 07, 2025.
Appointments
Comparative Medicine
Professor AdjunctPrimary
Other Departments & Organizations
Research
Copy Link
Overview
Medical Research Interests
Mental Disorders
ORCID
0000-0002-5379-8576
Research at a Glance
Yale Co-Authors
Frequent collaborators of Mihaly Hajos's published research.
Publications Timeline
A big-picture view of Mihaly Hajos's research output by year.
Tamas Horvath, DVM, PhD
Milan Stoiljkovic, MD, PhD
83Publications
5,411Citations
Publications
2025
Time saved in activities of daily living and whole‐brain volume: Post hoc analysis of a randomized feasibility trial of gamma oscillation treatment in participants with mild or moderate Alzheimer's disease
Kern R, Haaland B, Nicodemus‐Johnson J, Dickson S, Morgan M, Christensen J, Sabbagh M, Lee L, Hajós M, Riddle J, Seshagiri C, Howell C, Mallinckrodt C, Hendrix S. Time saved in activities of daily living and whole‐brain volume: Post hoc analysis of a randomized feasibility trial of gamma oscillation treatment in participants with mild or moderate Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2025, 11: e70118. PMID: 40501511, PMCID: PMC12152371, DOI: 10.1002/trc2.70118.Peer-Reviewed Original ResearchCitationsAltmetricConceptsWhole-brain volumeMini-Mental State ExaminationOpen-label extensionMild to moderate ADEvoked gamma oscillationsGamma oscillationsADCS-ADLActivities of daily livingWhole-brain atrophyPost Hoc AnalysisMeasures of whole-brain volumeMini-MentalState ExaminationAlzheimer's Disease Cooperative Study-ActivitiesAlzheimer's diseaseMonths of active treatmentDaily livingActive treatmentRandomized controlled trial phaseOpen-label extension phaseModerate Alzheimer's diseaseWhole-brain volume changesEffect of active treatmentMonths of progressionMemory consolidationA novel method for harmonization of PET image spatial resolution without phantoms
Carbonell F, Zijdenbos A, Hempel E, Hajós M, Bedell B. A novel method for harmonization of PET image spatial resolution without phantoms. EJNMMI Physics 2025, 12: 23. PMID: 40082316, PMCID: PMC11906943, DOI: 10.1186/s40658-025-00740-9.Peer-Reviewed Original ResearchCitationsConceptsPhantom imagesGroup of imagesLinear regression problemSpatial resolutionAlzheimer's Disease Neuroimaging InitiativeRegression problemPET imagingHoffman phantomResolution estimatesEstimation of spatial resolutionMultiple linear regression problemFourier domainImage spatial resolutionPhysical phantomAcquisition of imagesMaximum difference valuePhantom dataPhantomReconstruction parametersScanner modelsIn-planeVoxel sizeFourier transformSubject's PET imageIntensity plotsAlpha rhythm and Alzheimer’s disease: Has Hans Berger’s dream come true?
Babiloni C, Arakaki X, Baez S, Barry R, Benussi A, Blinowska K, Bonanni L, Borroni B, Bayard J, Bruno G, Cacciotti A, Carducci F, Carino J, Carpi M, Conte A, Cruzat J, D'Antonio F, Della Penna S, Del Percio C, De Sanctis P, Escudero J, Fabbrini G, Farina F, Fraga F, Fuhr P, Gschwandtner U, Güntekin B, Guo Y, Hajos M, Hallett M, Hampel H, Hanoğlu L, Haraldsen I, Hassan M, Hatlestad-Hall C, Horváth A, Ibanez A, Infarinato F, Jaramillo-Jimenez A, Jeong J, Jiang Y, Kamiński M, Koch G, Kumar S, Leodori G, Li G, Lizio R, Lopez S, Ferri R, Maestú F, Marra C, Marzetti L, McGeown W, Miraglia F, Moguilner S, Moretti D, Mushtaq F, Noce G, Nucci L, Ochoa J, Onorati P, Padovani A, Pappalettera C, Parra M, Pardini M, Pascual-Marqui R, Paulus W, Pizzella V, Prado P, Rauchs G, Ritter P, Salvatore M, Santamaria-García H, Schirner M, Soricelli A, Taylor J, Tankisi H, Tecchio F, Teipel S, Kodamullil A, Triggiani A, Valdes-Sosa M, Valdes-Sosa P, Vecchio F, Vossel K, Yao D, Yener G, Ziemann U, Kamondi A. Alpha rhythm and Alzheimer’s disease: Has Hans Berger’s dream come true? Clinical Neurophysiology 2025, 172: 33-50. PMID: 39978053, DOI: 10.1016/j.clinph.2025.02.256.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and ConceptsConceptsPathological agingAlzheimer's diseaseExpert panelAlpha rhythmAD patient’s qualityQuality of lifeAging-Alzheimer's AssociationCognitive impairmentCognitive declineClinical workupNeuroscience SocietyCortical circuitsAD patientsUS National InstitutesOlder adultsRoutine useSenile dementiaDecades of researchPatients' qualityClinical guidelinesOscillatory synchronizationCause of dementiaClinical applicationNIA-AADementiaCSF proteomics reveals changes in myelin and synaptic biology after Spectris treatment
Hajós M, Pandey K, Singer A, Duong D, Bitarafan S, Shpokayte M, Malchano Z, Kern R, Lah J, Levey A, Seyfried N. CSF proteomics reveals changes in myelin and synaptic biology after Spectris treatment. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2025, 11: e70051. PMID: 39935616, PMCID: PMC11812123, DOI: 10.1002/trc2.70051.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCellular lipid transportLipid transportWeeks of treatmentProteomic changesAlzheimer's diseaseCerebrospinal fluidGamma oscillationsTandem mass tag-mass spectrometryNeuroimmune functionDifferential expression analysisMyelin preservationUnbiased proteomic analysisBiological pathway analysisTreatment of ADSynaptic biologyAffected proteinsProteome modulationPhosphatidylcholine biosynthesisReduced brain volumeCSF proteome changesProtein networkSensory‐evoked gamma oscillationsExpression analysisBiochemical pathwaysBiological pathways
2024
Spectris™ treatment preserves corpus callosum structure in Alzheimer's disease
Da X, Hempel E, Brickman A, Hajós M, Kern R, Cimenser A. Spectris™ treatment preserves corpus callosum structure in Alzheimer's disease. Frontiers In Neurology 2024, 15: 1452930. PMID: 39479005, PMCID: PMC11522122, DOI: 10.3389/fneur.2024.1452930.Peer-Reviewed Original ResearchCitationsAltmetricParallel electrophysiological abnormalities due to COVID‐19 infection and to Alzheimer's disease and related dementia
Jiang Y, Neal J, Sompol P, Yener G, Arakaki X, Norris C, Farina F, Ibanez A, Lopez S, Al‐Ezzi A, Kavcic V, Güntekin B, Babiloni C, Hajós M. Parallel electrophysiological abnormalities due to COVID‐19 infection and to Alzheimer's disease and related dementia. Alzheimer's & Dementia 2024, 20: 7296-7319. PMID: 39206795, PMCID: PMC11485397, DOI: 10.1002/alz.14089.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricConceptsCOVID-19 patientsEEG abnormalitiesNeurophysiological abnormalitiesMild cognitive impairmentCognitive deficitsBrain activityAstrocyte reactivityPredicting long-term outcomesCognitive impairmentLong-term outcomesSlowing of EEGCognitive declineEfficacy of therapeutic interventionsIntrinsic brain activityLong COVIDElectrophysiological brain activityEEG slowingNeurological complicationsEpileptiform activityEEG monitoringEarly stages of neurodegenerative diseasesCognitive decline riskNeurovascular injuryLong COVID-19Acute phaseSafety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease
Hajós M, Boasso A, Hempel E, Shpokayte M, Konisky A, Seshagiri C, Fomenko V, Kwan K, Nicodemus-Johnson J, Hendrix S, Vaughan B, Kern R, Megerian J, Malchano Z. Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease. Frontiers In Neurology 2024, 15: 1343588. PMID: 38515445, PMCID: PMC10957179, DOI: 10.3389/fneur.2024.1343588.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAssessment of adverse eventsMild to moderate ADGamma oscillationsModerate ADAmyloid-related imaging abnormalitiesAlzheimer's diseaseMild-to-moderate Alzheimer's diseaseSecondary clinical outcome measuresTherapy systemPrimary outcome measureHigher adherence ratesWhole-brain volumeClinical outcome measuresSecondary outcome measuresModerate Alzheimer's diseaseDisease-modifying effectsBaseline MMSE scoreStudy discontinuationExperimental AD modelsWell-toleratedEfficacy outcomesClinical benefitAdverse eventsDaily treatmentClinical criteriaNoninvasive Gamma Sensory Stimulation May Reduce White Matter and Myelin Loss in Alzheimer’s Disease
Da X, Hempel E, Ou Y, Rowe O, Malchano Z, Hajós M, Kern R, Megerian J, Cimenser A. Noninvasive Gamma Sensory Stimulation May Reduce White Matter and Myelin Loss in Alzheimer’s Disease. Journal Of Alzheimer’s Disease 2024, 97: 359-372. PMID: 38073386, PMCID: PMC10789351, DOI: 10.3233/jad-230506.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsWhite matter atrophyActive treatment participantsMatter atrophyAlzheimer's diseaseMyelin lossTreatment participantsWhite matterNeuronal network functionT2-weighted MRIEarly disease interventionMRI outcomesClinical trialsEntorhinal regionWhite matter structuresHz stimulationMagnetic resonance imaging dataAfferent connectionsInclusion criteriaTherapeutic approachesAtrophySensory stimulationVolume assessmentDisease interventionDiseaseMyelin content
2023
Positive allosteric modulators of the α7 nicotinic acetylcholine receptor: SAR investigation around PNU-120596
Acker B, Badescu V, Berkenpas M, Groppi V, Hajós M, Higdon N, Hurst R, Jacobsen E, Margolis B, McWhorter W, Myers J, Piotrowski D, Rogers B, Sarapa D, Vetman T, Walker D, Wall T, Wilhite D, Wishka D, Xu W, Yates K. Positive allosteric modulators of the α7 nicotinic acetylcholine receptor: SAR investigation around PNU-120596. Bioorganic & Medicinal Chemistry Letters 2023, 93: 129433. PMID: 37557923, DOI: 10.1016/j.bmcl.2023.129433.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsΑ7 nicotinic acetylcholine receptorNicotinic acetylcholine receptorsPositive allosteric modulatorsAcetylcholine receptorsPNU-120596Powerful positive allosteric modulatorAllosteric modulatorsRat hippocampal neuronsPresence of acetylcholineDose-dependent mannerLigand-gated ion channelsCerebral cortexRat modelHippocampal neuronsSynaptic transmissionSensory gatingReceptorsEnhanced potencyIon channelsUnique biologyInitial structure-activity relationshipsSAR investigationCompound 16Structure-activity relationshipsThalamus
2022
TREM2 Deficiency Disrupts Network Oscillations Leading to Epileptic Activity and Aggravates Amyloid-β-Related Hippocampal Pathophysiology in Mice
Stoiljkovic M, Gutierrez KO, Kelley C, Horvath TL, Hajós M. TREM2 Deficiency Disrupts Network Oscillations Leading to Epileptic Activity and Aggravates Amyloid-β-Related Hippocampal Pathophysiology in Mice. Journal Of Alzheimer’s Disease 2022, 88: 837-847. PMID: 34120899, PMCID: PMC8898080, DOI: 10.3233/jad-210041.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAlzheimer's diseaseMicroglial functionTREM2 functionTheta-phase gamma-amplitude couplingHippocampal network functionSpontaneous epileptiform seizuresNetwork oscillationsTransgenic AD modelHippocampal neuronal excitabilityMyeloid cells 2Clinical Alzheimer's diseaseWild-type miceHippocampal network oscillationsHippocampal pathophysiologyProgressive dementiaTau pathologyUrethane anesthesiaAD pathophysiologyNeuronal excitabilityEpileptiform seizuresEpileptic activityAD modelTREM2Disease pathologyCells 2
Get In Touch
Copy Link